Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid-β Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway

ISSN: 1875-5828 (Online)
ISSN: 1567-2050 (Print)


Volume 11, 10 Issues, 2014


Download PDF Flyer




Current Alzheimer Research

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 38th of 194 in Clinical Neurology
  • 80th of 251 in Neurosciences

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Prof. Debomoy K. Lahiri
Department of Psychiatry Indiana University School of Medicine
Indianapolis, IN
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.796
5 - Year: 3.998

Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid-β Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway

Author(s): Marcella Reale, Marta Di Nicola, Lucia Velluto, Chiara D’Angelo, Erica Costantini, Debomoy K. Lahiri, Mohammad A. Kamal, Qian-sheng Yu and Nigel H. Greig

Affiliation: Dept. of Experimental and Clinical Sciences, Unit ofImmunodiagnostic and Molecular Pathology, University “G. D’Annunzio”, N.P.D., Ed. C, III lev., Via dei Vestini, 31, 66123 Chieti, Italy.

Abstract

Increasing evidence suggests that elevated production and/or reduced clearance of amyloid- β peptide (A β ) drives the early pathogenesis of Alzheimer’s disease (AD). A β soluble oligomers trigger a neurotoxic cascade that leads to neuronal dysfunction, neurodegeneration and, ultimately, clinical dementia. Inflammation, both within brain and systemically, together with a deficiency in the neurotransmitter acetylcholine (ACh) that underpinned the development of anticholinesterases for AD symptomatic treatment, are invariable hallmarks of the disease. The inter-relation between A β, inflammation and cholinergic signaling is complex, with each feeding back onto the others to drive disease progression. To elucidate these interactions plasma samples and peripheral blood mononuclear cells (PBMCs) were evaluated from healthy controls (HC) and AD patients. Plasma levels of acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and A β were significantly elevated in AD vs. HC subjects, and ACh showed a trend towards reduced levels. A β challenge of PBMCs induced a greater release of inflammatory cytokines interleukin-1 β (IL-1 β ), monocyte chemotactic protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF- α) from AD vs. HC subjects, with IL-10 being similarly affected. THP-1 monocytic cells, a cell culture counterpart of PBMCs and brain microglial cells, responded similarly to A β as well as to phytohaemagglutinin (PHA) challenge, to allow preliminary analysis of the cellular and molecular pathways underpinning A β-induced changes in cytokine expression. As amyloid- β precursor protein expression, and hence A β , has been reported regulated by particular cytokines and anticholinesterases, the latter were evaluated on A β- and PHA-induced chemocytokine expression. Co-incubation with selective AChE/BuChE inhibitors, (-)-phenserine (AChE) and (-)-cymserine analogues (BuChE), mitigated the rise in cytokine levels and suggest that augmentation of the cholinergic anti-inflammatory pathway may prove valuable in AD.

Keywords: Alzheimer’s disease, inflammation, cytokines, amyloid- β peptide (A β), IL-1β , TNF- α, MCP-1, IL-6, IL-10, acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), phenserine, cymserine, bisnorcymserine, phytohaemagglutinin (PHA) THP-1 cells, peripheral blood mononuclear cells (PBMCs), cholinesterase inhibitors.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 11
Issue Number: 6
First Page: 608
Last Page: 622
Page Count: 15
DOI: 10.2174/1567205010666131212113218
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science